Yellow Fever Vaccine

Summary

Yellow Fever Vaccine (CHEMBL2108816) is a phase-3 clinical-stage vaccine component (ATC J07BL01); indicated across 5 conditions including malaria and salmonella gastroenteritis.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Vaccine component
• ATC class: J07BL01
• Indications: 5 conditions
• Clinical trials: 25

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2108816
Name	Yellow Fever Vaccine
Type	Vaccine component
Max phase	3
ATC	J07BL01

Also known as: Stamaril, Yellow fever vaccine, Yellow fever virus strain 17d-204, Yellow fever, live attenuated, Yf-vax, YELLOW FEVER VACCINE

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

5 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
malaria	3	MONDO:0005136	EFO:0001068
Salmonella gastroenteritis	2	MONDO:0005950	EFO:0007475
atopic eczema	1	MONDO:0004980	EFO:0000274
Plasmodium falciparum malaria	0	MONDO:0005920	EFO:0007444

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 25.

Phase distribution

Phase	Trials
PHASE4	8
PHASE2	6
PHASE3	5
Not specified	4
PHASE1/PHASE2	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02555072	PHASE4	ACTIVE_NOT_RECRUITING	Immunity Period After One Dose of Yellow Fever Vaccine in Adults and Children (Paraiba Study)
NCT06148025	PHASE4	RECRUITING	Antibiotics and Vaccine Immune Responses Study
NCT00694655	PHASE4	COMPLETED	Human Immune Responses to Yellow Fever Vaccination
NCT01290055	PHASE4	COMPLETED	Turnover of Antigen Specific Lymphocytes and Monocytes After Immunization With the 17D Yellow Fever Vaccine
NCT02991495	PHASE4	COMPLETED	Immunogenicity and Safety of Fractional Doses of Yellow Fever Vaccines (YEFE)
NCT04059471	PHASE4	COMPLETED	Non- Inferiority Fractional-doses Trial for Yellow Fever Vaccine
NCT04083430	PHASE4	UNKNOWN	Cytotoxicity of Yellow Fever Specific CD8 T Cells Following YF-17D Vaccination
NCT05374317	PHASE4	COMPLETED	Study of the Safety and Immunogenicity of Reduced Doses of the US Yellow Fever Vaccine
NCT01345240	PHASE3	COMPLETED	Study to Evaluate Immunogenicity of the Hepatitis B Antigen of the GSK Biologicals’ Candidate Malaria Vaccine (257049)
NCT01436396	PHASE3	COMPLETED	Study of Yellow Fever Vaccine Administered With Tetravalent Dengue Vaccine in Healthy Toddlers
NCT01466387	PHASE3	COMPLETED	A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines When Administered Concomitantly With MenACWY in Adults
NCT02699099	PHASE3	COMPLETED	Immunogenicity and Safety Study of GSK Biologicals’ Candidate Malaria Vaccine Given at 6, 7.5 and 9 Months of Age in Co-administration With Measles, Rubella and Yellow Fever (YF) Vaccines Followed by a Booster of the Malaria Vaccine.
NCT05421611	PHASE3	COMPLETED	A Study of SII Yellow Fever Vaccine to Compare Safety and Immunogenicity With STAMARIL
NCT04942210	PHASE2	ACTIVE_NOT_RECRUITING	Study on an Investigational Yellow Fever Vaccine Compared With YF-VAX in Adults in the USA
NCT05011123	PHASE2	ACTIVE_NOT_RECRUITING	Study on an Investigational Yellow Fever Vaccine Compared With Stamaril in Adults in Europe and Asia
NCT06213506	PHASE2	ACTIVE_NOT_RECRUITING	A Study on the Safety, Reactogenicity, and Immune Response to the GVGH iNTS-GMMA Vaccine Against Invasive Nontyphoidal Salmonella in Adults, Children, and Infants
NCT06879327	PHASE2	RECRUITING	Infant Malaria Vaccine Schedule Optimization
NCT01943305	PHASE2	COMPLETED	The Role of Pre-existing Cross-reactive Antibodies in Determining the Efficacy of Vaccination in Humans
NCT04269265	PHASE1/PHASE2	COMPLETED	The Effect of Inflammation and Damage to Lymph Node Structures on Durable Protective Immunity Following Yellow Fever Vaccination
NCT05568953	PHASE2	UNKNOWN	An Experimental Medicine Decipher of a Minimum Correlate of Cellular Immunity
NCT04142086	PHASE1	COMPLETED	Dose-ranging Study of an Investigational Yellow Fever Candidate Vaccine in Adults
NCT01765413	Not specified	COMPLETED	Training Study to Characterize Biomarkers to Chickenpox and Yellow Fever Vaccines
NCT03430388	Not specified	COMPLETED	Yellow Fever Vaccine in Patients With Rheumatic Diseases
NCT03458780	Not specified	COMPLETED	Yellow Fever Immune Response at Single Cell Resolution
NCT05901454	Not specified	UNKNOWN	Yellow Fever Human Infection Model With YF-17D

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).